Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Cell & Gene Therapy Market Size and Forecast Report 2026-2036 | Market to Reach US$126.86 Billion at 17.3% CAGR as CRISPR, CAR-T and Scalable Manufacturing Drive Growth

globenewswire.com
ALLO Allogene Therapeutics is listed as a leading company in the cell & gene therapy market, suggesting its involvement in a growing industry. No specific sentiment is expressed towards the company. ATRA Atara Biotherapeutics is identified as a leading company in the cell & gene therapy market, implying its role in a developing sector. The article does not convey specific sentiment about the company. BEAM Beam Therapeutics is named as a leading company in the cell & gene therapy market, indicating its presence in a growing field. The article does not offer specific sentiment regarding Beam Therapeutics. BMRN BioMarin is listed as a leading company within the cell & gene therapy market, suggesting its active participation in this expanding sector. The article does not express a specific sentiment towards BioMarin. BMY Bristol-Myers Squibb is mentioned as a leading company in the cell & gene therapy market, indicating its involvement in a growing industry. The article does not provide specific sentiment towards the company. CRSP CRISPR Therapeutics is named as a leading company in the cell & gene therapy market, highlighting its position in a growing field. The article does not offer specific sentiment regarding CRISPR Therapeutics. GILD Gilead Sciences, Inc. is listed as a leading company in the cell & gene therapy market, indicating its participation in a growing sector. The article does not provide specific sentiment towards Gilead Sciences, Inc. INTC Intellia Therapeutics, Inc. is identified as a leading company in the cell & gene therapy market, suggesting its role in a developing sector. The article does not convey specific sentiment about Intellia Therapeutics, Inc. JNJ Johnson & Johnson is mentioned as a leading company in the cell & gene therapy market, indicating its involvement in a growing industry. The article does not provide specific sentiment towards Johnson & Johnson. NVS Novartis AG is named as a leading company in the cell & gene therapy market, highlighting its position in a growing field. The article does not offer specific sentiment regarding Novartis AG. VRTX Vertex Pharmaceuticals Incorporated is named as a leading company in the cell & gene therapy market, highlighting its position in a growing field. The article does not offer specific sentiment regarding Vertex Pharmaceuticals Incorporated.

Global Cell & Gene Therapy Market Size and Forecast Report 2026-2036 | Market to Reach US$126.86 Billion at 17.3% CAGR as CRISPR, CAR-T and Scalable Manufacturing Drive Growth Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -- "Cell & Gene Therapy Market Report 2026-2036" has been added to ResearchAndMarkets.com's offering.

The global Cell & Gene Therapy market is projected to grow from US$25.78 billion in 2026 to US$126.86 billion by 2036, representing a CAGR of 17.3%. This expansion reflects increasing clinical adoption, continued scientific progress, and the commercial advancement of innovative treatments across oncology, rare diseases, genetic disorders, and other high-need indications.

Scientific Innovation Accelerates Market Growth

Breakthroughs in gene editing, viral vector engineering, and cell therapy design are transforming the competitive landscape. CRISPR-based editing and next-generation CAR-T platforms are improving therapeutic precision, clinical outcomes, and manufacturing scalability. Advances in automation and production processes are also helping companies reduce manufacturing complexity and support broader commercialisation.

The integration of genomic data and personalised medicine is expanding the range of addressable conditions. Enhanced diagnostics and screening capabilities are supporting earlier identification of genetic diseases, more effective patient stratification, and faster development of clinical pipelines.

Disease Burden Supports Long-term Demand

The rising prevalence of genetic, congenital, chronic, and oncological diseases is sustaining demand for cell & gene therapies. Expanding clinical evidence, a growing number of regulatory approvals, and investment in specialised treatment centres are moving these therapies further into mainstream healthcare. Oncology and rare disease indications remain central to market development, while cardiovascular, neurological, infectious, and ophthalmic applications present additional growth opportunities.

Pricing and Access Remain Key Market Constraints

High upfront treatment costs continue to restrict patient access, with some therapies exceeding US$2 million per patient. Healthcare systems and payers face significant affordability and budget planning challenges, while reimbursement frameworks remain uneven across markets.

Outcomes-based agreements and instalment payment models are gaining attention, but adoption is not yet widespread. Reimbursement delays, limited treatment infrastructure, and complex patient eligibility requirements may slow market uptake. Companies that develop sustainable pricing strategies and generate compelling long-term clinical evidence will be better positioned to secure market access.

Trade Policy and Supply Chain Pressures

The Cell & Gene Therapy market relies on international supply chains for specialised biological materials, reagents, vectors, and manufacturing equipment. U.S. trade tariffs may increase the cost of imported inputs and create additional uncertainty, particularly for smaller biotechnology companies. These pressures can influence development timelines, production capacity, and commercial scalability.

In response, market participants are investing in resilient, localised manufacturing infrastructure and stronger supplier networks. Key commercial considerations include:

Competitive Landscape and Company Intelligence

Large pharmaceutical companies and specialist biotechnology firms are expanding pipelines, forming strategic alliances, and increasing manufacturing scale-up. Competitive differentiation is increasingly determined by clinical pipeline strength, technology innovation, production scalability, regulatory execution, and commercial readiness.

The report profiles leading Cell & Gene Therapy companies, including Adaptimmune, ALLOGENE THERAPEUTICS, Atara Biotherapeutics, Inc., Beam Therapeutics, BioMarin, Bristol-Myers Squibb Company, Catalent, Inc, CRISPR Therapeutics, Genetix Biotherapeutics Inc., GenScript, Gilead Sciences, Inc., Intellia Therapeutics, Inc., Johnson & Johnson, Lonza, MeiraGTx Limited, Novartis AG, Sarepta Therapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Vertex Pharmaceuticals Incorporated.

Each company profile assesses business operations, financial positioning, product and technology capabilities, and strategic outlook.

Cell & Gene Therapy Market Segmentation

Geographic Market Coverage

The analysis includes regional and national forecasts across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Covered markets include the U.S., Canada, Germany, UK, France, Italy, Spain, Russia, Japan, China, India, Australia, South Korea, Singapore, Brazil, Mexico, Argentina, GCC countries, and South Africa.

Report Scope and Strategic Value

The report provides global revenue forecasts to 2036, segment-level modelling, regional and national analysis, and competitive intelligence. It examines market drivers, restraints, pricing trends, reimbursement developments, regulatory influences, supply chain risks, and future revenue opportunities.

Visiongain also provides bespoke intelligence and customisation, including tailored forecasts, competitive benchmarking, and regulatory analysis. This market intelligence enables pharmaceutical companies, biotechnology firms, investors, healthcare providers, and other stakeholders to evaluate opportunities, manage commercial risk, and strengthen their position in the rapidly expanding global Cell & Gene Therapy market.

Key Attributes:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/1tb7gi

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.